Cargando…

Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial

Objective. To determine whether a combination of borage seed oil rich in gamma linolenic acid (GLA) and fish oil rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either oil alone for treatment of rheumatoid arthritis (RA). Methods. Patients were randomized into a dou...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, George W., Leung, Katherine, Rossetti, Ronald G., VanBuskirk, Susan, Sharp, John T., Zurier, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977504/
https://www.ncbi.nlm.nih.gov/pubmed/24803948
http://dx.doi.org/10.1155/2014/857456
_version_ 1782310429444276224
author Reed, George W.
Leung, Katherine
Rossetti, Ronald G.
VanBuskirk, Susan
Sharp, John T.
Zurier, Robert B.
author_facet Reed, George W.
Leung, Katherine
Rossetti, Ronald G.
VanBuskirk, Susan
Sharp, John T.
Zurier, Robert B.
author_sort Reed, George W.
collection PubMed
description Objective. To determine whether a combination of borage seed oil rich in gamma linolenic acid (GLA) and fish oil rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either oil alone for treatment of rheumatoid arthritis (RA). Methods. Patients were randomized into a double-blind, 18-month trial. Mixed effects models compared trends over time in disease activity measures. Results. No significant differences were observed in changes in disease activity among the three randomized groups. Each group exhibited significant reductions in disease activity (DAS28) at 9 months (fish: −1.56[−2.16, −0.96], borage: −1.33[−1.83, −0.84], combined: −1.18[−1.83, −0.54]) and in CDAI (fish: −16.95[−19.91, −13.98], borage: −11.20[−14.21, −8.19], and combined: −10.31[−13.61, −7.01]). There were no significant differences in change of RA medications among the three groups. Reduced disease activity in study patients was similar to matched patients from an RA registry, and reduction in DMARD use was greater (P < 0.03) in study patients. Conclusion. All 3 treatment groups exhibited similar meaningful clinical responses after 9 months, improvements which persisted for 18 months, and a response similar to matched patients from an RA registry. Study patients were able to reduce DMARD therapy given in combination with TNF antagonists to a greater extent than registry patients. This paper is dedicated to the memory of Dr. John T. Sharp, M.D., a pioneer and innovator in the field of musculoskeletal radiology
format Online
Article
Text
id pubmed-3977504
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39775042014-05-06 Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial Reed, George W. Leung, Katherine Rossetti, Ronald G. VanBuskirk, Susan Sharp, John T. Zurier, Robert B. Evid Based Complement Alternat Med Research Article Objective. To determine whether a combination of borage seed oil rich in gamma linolenic acid (GLA) and fish oil rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either oil alone for treatment of rheumatoid arthritis (RA). Methods. Patients were randomized into a double-blind, 18-month trial. Mixed effects models compared trends over time in disease activity measures. Results. No significant differences were observed in changes in disease activity among the three randomized groups. Each group exhibited significant reductions in disease activity (DAS28) at 9 months (fish: −1.56[−2.16, −0.96], borage: −1.33[−1.83, −0.84], combined: −1.18[−1.83, −0.54]) and in CDAI (fish: −16.95[−19.91, −13.98], borage: −11.20[−14.21, −8.19], and combined: −10.31[−13.61, −7.01]). There were no significant differences in change of RA medications among the three groups. Reduced disease activity in study patients was similar to matched patients from an RA registry, and reduction in DMARD use was greater (P < 0.03) in study patients. Conclusion. All 3 treatment groups exhibited similar meaningful clinical responses after 9 months, improvements which persisted for 18 months, and a response similar to matched patients from an RA registry. Study patients were able to reduce DMARD therapy given in combination with TNF antagonists to a greater extent than registry patients. This paper is dedicated to the memory of Dr. John T. Sharp, M.D., a pioneer and innovator in the field of musculoskeletal radiology Hindawi Publishing Corporation 2014 2014-03-19 /pmc/articles/PMC3977504/ /pubmed/24803948 http://dx.doi.org/10.1155/2014/857456 Text en Copyright © 2014 George W. Reed et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Reed, George W.
Leung, Katherine
Rossetti, Ronald G.
VanBuskirk, Susan
Sharp, John T.
Zurier, Robert B.
Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title_full Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title_fullStr Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title_full_unstemmed Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title_short Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: An 18-Month, Randomized, and Double-Blind Trial
title_sort treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977504/
https://www.ncbi.nlm.nih.gov/pubmed/24803948
http://dx.doi.org/10.1155/2014/857456
work_keys_str_mv AT reedgeorgew treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial
AT leungkatherine treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial
AT rossettironaldg treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial
AT vanbuskirksusan treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial
AT sharpjohnt treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial
AT zurierrobertb treatmentofrheumatoidarthritiswithmarineandbotanicaloilsan18monthrandomizedanddoubleblindtrial